Definium Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $3.65B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 28, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | During market hours | – | $-1.44 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | – | $-0.71 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 29, 2025 | During market hours | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 31, 2025 | During market hours | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 6, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | Before market open | – | – | – |
Press releases
Announcements Definium Therapeutics filed with the SEC
Therapeutics Announces Positive Topline Results from Phase 3
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Phase 3 Panorama Study Topline Data Readout
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Definium Therapeutics Announces Positive Topline
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Phase 3 Voyage Study Topline Data Readout
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
NEW YORK, June 22, 2026 – Definium
Material agreement · Other events · EX-99.1 to Form 8-K
Announces Pricing of $700 Million Upsized Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Definium Therapeutics Announces Positive Topline
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Phase 3 Emerge Study Topline Data Readout
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Program Overview Lysergide tartrate DT120 01
Other events · EX-99.1 to Form 8-K
Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Investor & Analyst Day April 22, 2026
Other events · EX-99.2 to Form 8-K
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026
Results of operations · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Program Overview DT120 ODT Lysergide tartrate 01
Results of operations · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
MindMed Reports Q3 2025 Financial Results and Business Updates
Results of operations · Other events · EX-99.1 to Form 8-K
Program Overview MM120 ODT Lysergide D-tartrate
Results of operations · Other events · EX-99.2 to Form 8-K
Mind Medicine (MindMed) Inc. Announces Proposed
Material agreement · Other events · EX-99.1 to Form 8-K
Mind Medicine (MindMed) Inc. Announces Pricing
Material agreement · Other events · EX-99.2 to Form 8-K
Program Overview MM120 ODT Lysergide D - tartrate
Results of operations · Other events · EX-99.1 to Form 8-K
MindMed Reports Q2 2025 Financial Results and Business Updates
Results of operations · Other events · EX-99.1 to Form 8-K
2025 On Track and Executing MM120-300 for GAD Phase 3 topline readout 1H 2026 ANTICIPATED MILESTONES MM120-301 for GAD Phase 3 topline readout 2H 2026 MM120-310 for MDD Phase 3 topline readout 2H 2026
Results of operations · Other events · EX-99.2 to Form 8-K
Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MindMed Reports First Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)
Other events · EX-99.1 to Form 8-K
MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates
Results of operations · EX-99.1 to Form 8-K
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder
Other events · EX-99.1 to Form 8-K
MM120 ODT LSD D - tartrate Program Overview
Executive or director change · Other events · EX-99.1 to Form 8-K
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
Other events · EX-99.1 to Form 8-K
MindMed Reports Third Quarter 2024 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
MindMed Reports Second Quarter 2024 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Mind Medicine (MindMed) Inc. Announces Proposed
Material agreement · Results of operations · Other events · EX-99.1 to Form 8-K
Mind Medicine (MindMed) Inc. Announces Pricing
Material agreement · Results of operations · Other events · EX-99.2 to Form 8-K
Corporate Presentation | August 2024 Experienced Leadership with a Proven Track Record 4 Strong Experience in Brain Health Innovation 1 1. Representative of approved drugs developed by MindMed employees
Material agreement · Results of operations · Other events · EX-99.3 to Form 8-K
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
Other events · EX-99.1 to Form 8-K
MindMed Reports First Quarter 2024 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K